12:00 AM
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Solanezumab: Additional Phase III data

Eli Lilly reported additional data from the 18-month, double-blind, international Phase III EXPEDITION1 and EXPEDITION2 trials in over 2,050 patients with AD who received 400 mg IV solanezumab every 4 weeks. Pooled data from both trials showed that in patients with mild AD, solanezumab led to a significant 34% reduction in cognitive decline as measured by ADAS-Cog14 scores from baseline to week 80 vs. placebo (p=0.001). Pooled data also showed that patients with mild AD had a non-significant 17% reduction in functional decline as measured by ADCS-ADL scores vs. placebo (p=0.057). Additionally, solanezumab significantly improved MMSE scores from...

Read the full 468 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >